Drug intelligence / Profile preview

TCellMune-LA

Development stage: Preclinical
Lead developer: Vaxxit
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

TCellMune-LA is a live attenuated herpes simplex virus (HSV) vaccine candidate being developed by Vaxxit. It is designed to elicit T cell-mediated immunity against both HSV-1 and HSV-2. The vaccine utilizes a weakened form of the virus to stimulate a protective immune response, aiming to prevent or treat infections associated with oral and genital herpes. As of the latest reports, the program is in the preclinical stage of development.

Other names: TCellMune LA

Beyond the preview

Go deeper on TCellMune-LA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCellMune-LA.

Explore the full profile